Plain-English translation of NCT06202001 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a Phase I/II study testing a combination of three medications—irinotecan, trifluridine/tipiracil (TAS-102), and bevacizumab—for people with advanced colorectal cancer that has spread to other parts of the body. The first part of the trial finds the safest and most effective dose of this medication combination, and the second part tests how well it works.
People whose advanced colorectal cancer no longer responds to the standard first-line treatment need new options. This trial is exploring whether combining these three medications might offer better results for patients at this stage of their disease.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination every 14 days in repeated cycles. The treatment involves taking pills by mouth twice daily for 5 days, plus two intravenous infusions on day 1 of each cycle. The study starts with lower doses and gradually increases them to find the safest effective dose. You would continue treatment as long as the medication is helping and you can tolerate it, with regular doctor visits and imaging tests to monitor how your cancer responds.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China